CoChat
Sign Up
Cited by 57Mobile Health and mHealth ApplicationsInnovative Human-Technology InteractionUsability and User Interface Design

The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach

Open access
Ector, Geneviève ICG, Westerweel, Peter E, Hermens, Rosella PMG, Braspenning, Karin AE, Heeren, Barend CM, Vinck, Oscar MF, de Jong, Jan JM, Janssen, Jeroen JWM +1 more·2020·Journal of Medical Internet Research
DOI 10.2196/15895PMC PMC7260663

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Background: With the global rise in chronic health conditions, health care is transforming, and patient empowerment is being emphasized to improve treatment outcomes and reduce health care costs. Patient-centered innovations are needed. We focused on patients with chronic myeloid leukemia (CML), a chronic disease with a generally good long-term prognosis because of the advent of tyrosine kinase inhibitors. However, both medication adherence by patients and guideline adherence by physicians are suboptimal, unnecessarily jeopardizing treatment outcomes. Objective: The aim of this study was to develop a patient-centered innovation for patients with CML using a design thinking methodology. Methods: The 5 phases of design thinking (ie, empathize, define, ideate, prototype, and test) were completed, and each phase started with the patient. Stakeholders and end users were identified and interviewed, and observations in the care system were made. Using tools in human-centered design, problems were defined and various prototypes of solutions were generated. These were evaluated by patients and stakeholders and then further refined. Results: The patients desired (1) insights into their own disease; (2) insights into the symptoms experienced, both in terms of knowledge and comprehension; and (3) improvements in the organization of care delivery. A web-based platform, CMyLife, was developed and pilot-tested. It has multiple features, all targeting parts of the bigger solution, including a website with reliable information and a forum, a guideline app, personal medical records with logs of symptoms and laboratory results (including a molecular marker and linked to the guideline app), tailored feedback based on the patients’ symptoms and/or results, screen-to-screen consulting, delivery of medication, and the collection of blood samples at home. Conclusions: The multifeatured innovation, CMyLife, was developed in a multidisciplinary way and with active patient participation. The aim of developing CMyLife was to give patients the tools to monitor their results, interpret these results, and act on them. With this tool, they are provided with the know-how to consider their results in relation to their personal care process. Whether CMyLife achieves its goal and the evaluation of the added value will be the focus of future studies. CML could become the first malignancy for which patients are able to monitor and manage their disease by themselves.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2196/15895

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • StressProffen [22] and CMyLife [14] demonstrated how usability testing can identify challenges with data entry and workflow guidance, which directly informed revisions to interface design and content presentation to improve navigation pathways.

    “For example, tools such as StressProffen [22] and CMyLife [14] demonstrated how usability testing can identify challenges with data entry and workflow guidance, which directly informed revisions to interface design and content presentation to improve navigation pathways.”

    From User-Centered Design for Digital Patient-Navigation Tools in Oncology: Scoping Review (2026) · cites this paper as [14]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

  • The CMyLife platform presented by Ector et al. was codeveloped to help patients interpret their own test results and take action across their care journey, reframing navigation as patient empowerment rather than simple wayfinding.

    “The CMyLife platform presented by Ector et al [14] was codeveloped to help patients interpret their own test results and take action across their care journey, reframing navigation as patient empowerment rather than simple wayfinding.”

    From User-Centered Design for Digital Patient-Navigation Tools in Oncology: Scoping Review (2026) · cites this paper as [14]

  • UCD/HCD approaches prioritize the needs, preferences, and lived experiences of end users through iterative, participatory design processes that foster usability, engagement, and real-world applicability.

    “These approaches prioritize the needs, preferences, and lived experiences of end users (ie, patients, caregivers, and providers) through iterative, participatory design processes that foster usability, engagement, and real-world applicability [13,14].”

    From User-Centered Design for Digital Patient-Navigation Tools in Oncology: Scoping Review (2026) · cites this paper as [14]

  • CMyLife, developed for individuals with chronic myeloid leukemia, equipped patients with tools to track and interpret their results while aligning design decisions with survivor priorities identified during participatory sessions.

    “CMyLife presented by Ector et al [14], developed for individuals with chronic myeloid leukemia, equipped patients with tools to track and interpret their results while aligning design decisions with survivor priorities identified during participatory sessions.”

    From User-Centered Design for Digital Patient-Navigation Tools in Oncology: Scoping Review (2026) · cites this paper as [14]

  • StressProffen [22] and CMyLife [14] illustrate how iterative design can expand navigation beyond tracking to include psychosocial support and relational care.

    “Tools such as StressProffen [22] and CMyLife [14] illustrate how iterative design can expand navigation beyond tracking to include psychosocial support and relational care.”

    From User-Centered Design for Digital Patient-Navigation Tools in Oncology: Scoping Review (2026) · cites this paper as [14]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. [2]Holman H Lorig K Patients as partners in managing chronic disease. Partnership is a prerequisite for effective and efficient health care Br Med J 2000 02 26 320 7234 526 7 10.1136/bmj.320.7234.526 10688539 10688539 PMC1117581 · DOI
  2. [4]Pulvirenti M McMillan J Lawn S Empowerment, patient centred care and self-management Health Expect 2014 06 17 3 303 10 10.1111/j.1369-7625.2011.00757.x 22212306 22212306 PMC5060728 · DOI
  3. [5]Bauman AE Fardy HJ Harris PG Getting it right: why bother with patient-centred care? Med J Aust 2003 09 1 179 5 253 6 12924973 bau10856_fm 12924973
  4. [6]Jacobson RE Information Design 2000 Cambridge The MIT Press
  5. [7]Brown T Design thinking Harv Bus Rev 2008 06 86 6 84 92, 141 18605031 18605031
  6. [8]Luchs M Luchs M Swan S Griffin A A brief introduction to design thinking Design Thinking: New Product Development Essentials from the PDMA 2015 New Jersey, USA John Wiley & Sons Inc 1 12
  7. [9]Criscitelli T Goodwin W Applying human-centered design thinking to enhance safety in the OR AORN J 2017 04 105 4 408 12 10.1016/j.aorn.2017.02.004 28336030 S0001-2092(17)30108-4 28336030 · DOI
  8. [10]Dandara C Endrenyi L Kolker E Hekim N Steuten LM Güngör K Aklillu E Özdemir V Precision Medicine 2.0: The Rise of Glocal Innovation, Superconnectors, and Design Thinking OMICS 2016 09 20 9 493 5 10.1089/omi.2016.0129 27631187 27631187 · DOI
  9. [11]Eckman M Gorski I Mehta K Leveraging design thinking to build sustainable mobile health systems J Med Eng Technol 2016 40 7-8 422 30 10.1080/03091902.2016.1218560 27535325 27535325 · DOI
  10. [12]Ferreira F Song E Gomes H Garcia E Ferreira L New mindset in scientific method in the health field: Design Thinking Clinics (Sao Paulo) 2015 12 70 12 770 2 10.6061/clinics/2015(12)01 26735214 S1807-59322015001200770 26735214 PMC4676318 · DOI
  11. [13]Altman M Huang TT Breland JY Design thinking in health care Prev Chronic Dis 2018 09 27 15 E117 10.5888/pcd15.180128 30264690 E117 30264690 PMC6178900 · DOI · Paper page
  12. [14]Bower H Björkholm M Dickman PW Höglund M Lambert PC Andersson TM Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population J Clin Oncol 2016 08 20 34 24 2851 7 10.1200/JCO.2015.66.2866 27325849 JCO.2015.66.2866 27325849 · DOI · Paper page
  13. [15]Huang X Cortes J Kantarjian H Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy Cancer 2012 06 15 118 12 3123 7 10.1002/cncr.26679 10.1002/cncr.26679 22294282 22294282 PMC3342429 · DOI
  14. [16]Baccarani M Deininger MW Rosti G Hochhaus A Soverini S Apperley JF Cervantes F Clark RE Cortes JE Guilhot F Hjorth-Hansen H Hughes TP Kantarjian HM Kim D Larson RA Lipton JH Mahon F Martinelli G Mayer J Müller MC Niederwieser D Pane F Radich JP Rousselot P Saglio G Saußele S Schiffer C Silver R Simonsson B Steegmann J Goldman JM Hehlmann R European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Blood 2013 08 8 122 6 872 84 10.1182/blood-2013-05-501569 23803709 blood-2013-05-501569 23803709 PMC4915804 · DOI
  15. [17]O'Brien S Berman E Borghaei H Deangelo DJ Devetten MP Devine S Erba HP Gotlib J Jagasia M Moore JO Mughal T Pinilla-Ibarz J Radich JP Shah Md NP Shami PJ Smith BD Snyder DS Tallman MS Talpaz M Wetzler M National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia J Natl Compr Canc Netw 2009 10 7 9 984 1023 10.6004/jnccn.2009.0065 19878641 19878641 · DOI
  16. [18]Goldberg SL Monitoring chronic myeloid leukemia in the real world: gaps and opportunities Clin Lymphoma Myeloma Leuk 2015 12 15 12 711 4 10.1016/j.clml.2015.08.088 26433907 S2152-2650(15)01246-X 26433907 · DOI
  17. [19]Guérin A Chen L Dea K Wu EQ Goldberg SL Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase Curr Med Res Opin 2014 07 30 7 1345 52 10.1185/03007995.2014.904281 24640967 24640967 · DOI
  18. [20]Saleh MN Haislip S Sharpe J Hess T Gilmore J Jackson J Sail KR Ericson SG Chen L Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting Curr Med Res Opin 2014 04 30 4 529 36 10.1185/03007995.2013.858621 24156689 24156689 · DOI
  19. [21]Goldberg SL Chen L Guerin A Macalalad AR Liu N Kaminsky M Ericson SG Wu EQ Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib Curr Med Res Opin 2013 09 29 9 1075 82 10.1185/03007995.2013.812034 23738923 23738923 · DOI
  20. [22]Marin D Bazeos A Mahon F Eliasson L Milojkovic D Bua M Apperley JF Szydlo R Desai R Kozlowski K Paliompeis C Latham V Foroni L Molimard M Reid A Rezvani K de Lavallade H Guallar C Goldman J Khorashad JS Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib J Clin Oncol 2010 05 10 28 14 2381 8 10.1200/JCO.2009.26.3087 20385986 JCO.2009.26.3087 20385986 PMC6366340 · DOI
  21. [23]Noens L van Lierde MA de Bock R Verhoef G Zachée P Berneman Z Martiat P Mineur P van Eygen K MacDonald K De Geest S Albrecht T Abraham I Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Blood 2009 05 28 113 22 5401 11 10.1182/blood-2008-12-196543 19349618 blood-2008-12-196543 19349618 · DOI
  22. [24]Latremouille-Viau D Guerin A Gagnon-Sanschagrin P Dea K Cohen BG Joseph GJ Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency J Manag Care Spec Pharm 2017 02 23 2 214 24 10.18553/jmcp.2017.23.2.214 10.18553/jmcp.2017.23.2.214 28125373 28125373 PMC10397939 · DOI
  23. [25]Efficace F Baccarani M Breccia M Saussele S Abel G Caocci G Guilhot F Cocks K Naeem A Sprangers M Oerlemans S Chie W Castagnetti F Bombaci F Sharf G Cardoni A Noens L Pallua S Salvucci M Nicolatou-Galitis O Rosti G Mandelli F International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24 Qual Life Res 2014 04 23 3 825 36 10.1007/s11136-013-0523-5 24026634 24026634 · DOI
  24. [26]Steegmann JL Baccarani M Breccia M Casado LF García-Gutiérrez V Hochhaus A Kim D Kim TD Khoury HJ Le Coutre P Mayer J Milojkovic D Porkka K Rea D Rosti G Saussele S Hehlmann R Clark RE European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Leukemia 2016 08 30 8 1648 71 10.1038/leu.2016.104 27121688 leu2016104 27121688 PMC4991363 · DOI
  25. [27]Efficace F Rosti G Aaronson N Cottone F Angelucci E Molica S Vignetti M Mandelli F Baccarani M Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia Haematologica 2014 04 99 4 788 93 10.3324/haematol.2013.093724 24241488 haematol.2013.093724 24241488 PMC3971090 · DOI
  26. [32]Ohno T Toyota Production System: Beyond Large-scale Production 1978 Boca Raton, Florida CRC Press
  27. [33]Vianna M Vianna Y Adler I Lucena B Russo B Design Thinking: Business Innovation 2013 Rio de Janeiro MJV Press
  28. [34]Saußele S Richter J Hochhaus A Mahon FX The concept of treatment-free remission in chronic myeloid leukemia Leukemia 2016 08 30 8 1638 47 10.1038/leu.2016.115 27133824 leu2016115 27133824 PMC4980559 · DOI
  29. [35]Hughes TP Ross DM Moving treatment-free remission into mainstream clinical practice in CML Blood 2016 07 7 128 1 17 23 10.1182/blood-2016-01-694265 27013442 blood-2016-01-694265 27013442 · DOI
  30. [36]Saglio G Sharf G Almeida A Bogdanovic A Bombaci F Čugurović J Deekes N Garcia-Gutiérrez V de Jong J Narbutas Š Westerweel P Zackova D Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective Clin Lymphoma Myeloma Leuk 2018 06 18 6 375 9 10.1016/j.clml.2018.04.005 29753691 S2152-2650(18)30385-9 29753691 · DOI
  31. [40]Jackson J Chen L Sail K Ericson S Haislip S Sharpe J Gilmore J Saleh MN Monitoring Patterns and Subsequent Outcomes Among Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) Treated with Imatinib in a Community Setting Blood 2012 120 21 2066 10.1182/blood.V120.21.2066.2066 24156689 · DOI
  32. [41]Geelen IG Thielen N Janssen JJ Hoogendoorn M Roosma TJ Willemsen SP Visser O Cornelissen JJ Westerweel PE Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia Haematologica 2017 11 102 11 1842 9 10.3324/haematol.2017.174953 28860339 haematol.2017.174953 28860339 PMC5664388 · DOI
  33. [42]Geelen IG Thielen N Janssen JJ Hoogendoorn M Roosma TJ Willemsen SP Valk PJ Visser O Cornelissen JJ Westerweel PE Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival Haematologica 2017 12 102 12 e486 9 10.3324/haematol.2017.175265 28860340 haematol.2017.175265 28860340 PMC5709118 · DOI
  34. [43]Mahon F Réa D Guilhot J Guilhot F Huguet F Nicolini F Legros L Charbonnier A Guerci A Varet B Etienne G Reiffers J Rousselot P Intergroupe Français des Leucémies Myéloïdes Chroniques Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 2010 11 11 11 1029 35 10.1016/S1470-2045(10)70233-3 20965785 S1470-2045(10)70233-3 20965785 · DOI
  35. [44]Ross DM Branford S Seymour JF Schwarer AP Arthur C Yeung DT Dang P Goyne JM Slader C Filshie RJ Mills AK Melo JV White DL Grigg AP Hughes TP Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study Blood 2013 07 25 122 4 515 22 10.1182/blood-2013-02-483750 23704092 blood-2013-02-483750 23704092 · DOI
  36. [45]Saussele S Richter J Guilhot J Gruber FX Hjorth-Hansen H Almeida A Janssen JJ Mayer J Koskenvesa P Panayiotidis P Olsson-Strömberg U Martinez-Lopez J Rousselot P Vestergaard H Ehrencrona H Kairisto V Poláková KM Müller MC Mustjoki S Berger MG Fabarius A Hofmann W Hochhaus A Pfirrmann M Mahon F EURO-SKI investigators Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Lancet Oncol 2018 06 19 6 747 57 10.1016/S1470-2045(18)30192-X 29735299 S1470-2045(18)30192-X 29735299 · DOI
  37. [46]Breccia M Efficace F Alimena G Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors Leuk Res 2012 07 36 7 804 5 10.1016/j.leukres.2012.02.032 22459331 S0145-2126(12)00121-X 22459331 · DOI
  38. [47]Breccia M Efficace F Sica S Abruzzese E Cedrone M Turri D Gobbi M Carella AM Gozzini A Usala E Cavazzini F Danise P Tiribelli M Binotto G Pregno P Bocchia M Gaidano G Crugnola M Bonifacio M Avanzini P Celesti F Guella A Martino B Annunziata M Luciano L Stagno F Vallisa D Pungolino E Iurlo A Rambaldi A Nardiello I Orlandi E Gambacorti-Passerini C Alimena G Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients Leuk Res 2015 10 39 10 1055 9 10.1016/j.leukres.2015.07.004 26282944 S0145-2126(15)30347-7 26282944 · DOI
  39. [48]Efficace F Baccarani M Rosti G Cottone F Castagnetti F Breccia M Alimena G Iurlo A Rossi AR Pardini S Gherlinzoni F Salvucci M Tiribelli M Vignetti M Mandelli F Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study Br J Cancer 2012 09 4 107 6 904 9 10.1038/bjc.2012.348 10.1038/bjc.2012.348 22871884 bjc2012348 22871884 PMC3464760 · DOI
  40. [49]Eliasson L Clifford S Barber N Marin D Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed Leuk Res 2011 05 35 5 626 30 10.1016/j.leukres.2010.10.017 21095002 S0145-2126(10)00510-2 21095002 · DOI
  41. [50]Unnikrishnan R Veeraiah S Mani S Rajendranath R Rajaraman S Elangovan GS Radhakrishnan V Ganesan TS Sagar TG Ganesan P Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib Clin Lymphoma Myeloma Leuk 2016 06 16 6 366 71.e3 10.1016/j.clml.2016.02.040 27052853 S2152-2650(16)00100-2 27052853 · DOI
  42. [51]Rychter A Jerzmanowski P Hołub A Specht-Szwoch Z Kalinowska V Tęgowska U Seferyńska I Kołkowska-Leśniak A Lech-Marańda E Góra-Tybor J Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors Med Oncol 2017 06 34 6 104 10.1007/s12032-017-0958-6 28444623 10.1007/s12032-017-0958-6 28444623 PMC5405100 · DOI
  43. [52]Ibrahim AR Eliasson L Apperley JF Milojkovic D Bua M Szydlo R Mahon F Kozlowski K Paliompeis C Foroni L Khorashad JS Bazeos A Molimard M Reid A Rezvani K Gerrard G Goldman J Marin D Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy Blood 2011 04 7 117 14 3733 6 10.1182/blood-2010-10-309807 21346253 blood-2010-10-309807 21346253 PMC6143152 · DOI
  44. [53]Kekäle M Talvensaari K Koskenvesa P Porkka K Airaksinen M Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians Patient Prefer Adherence 2014 8 1619 27 10.2147/PPA.S70712 10.2147/PPA.S70712 25473270 ppa-8-1619 25473270 PMC4246993 · DOI
  45. [54]Stefanovic S Wallwiener M Karic U Domschke C Katic L Taran F Pesic A Hartkopf A Hadji P Teufel M Schuetz F Sohn C Fasching P Schneeweiss A Brucker S Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications Support Care Cancer 2017 02 25 2 549 58 10.1007/s00520-016-3437-2 27747478 10.1007/s00520-016-3437-2 27747478 · DOI
  46. [56]de Marchi F Medeot M Fanin R Tiribelli M How could patient reported outcomes improve patient management in chronic myeloid leukemia? Expert Rev Hematol 2017 01 10 1 9 14 10.1080/17474086.2017.1262758 27858461 27858461 · DOI
  47. [57]Kuijpers W Groen WG Oldenburg HS Wouters MW Aaronson NK van Harten WH eHealth for breast cancer survivors: use, feasibility and impact of an interactive portal JMIR Cancer 2016 05 10 2 1 e3 10.2196/cancer.5456 28410178 v2i1e3 28410178 PMC5369634 · DOI · Paper page
  48. [58]Groen WG Kuijpers W Oldenburg HS Wouters MW Aaronson NK van Harten WH Supporting lung cancer patients with an interactive patient portal: feasibility study JMIR Cancer 2017 08 8 3 2 e10 10.2196/cancer.7443 28790025 v3i2e10 28790025 PMC5566630 · DOI
  49. [59]van Bruinessen IR van Weel-Baumgarten EM Gouw H Zijlstra JM van Dulmen S An integrated process and outcome evaluation of a web-based communication tool for patients with malignant lymphoma: randomized controlled trial J Med Internet Res 2016 07 29 18 7 e206 10.2196/jmir.5877 27473173 v18i7e206 27473173 PMC4982912 · DOI
  50. [61]Kaal SE Husson O van Dartel F Hermans K Jansen R Manten-Horst E Servaes P van de Belt T Engelen LJ Prins JB Verberne S van der Graaf WT Online support community for adolescents and young adults (AYAs) with cancer: user statistics, evaluation, and content analysis Patient Prefer Adherence 2018 12 2615 22 10.2147/PPA.S171892 10.2147/PPA.S171892 30584285 ppa-12-2615 30584285 PMC6287522 · DOI
  51. [62]Bender JL Jimenez-Marroquin MC Ferris LE Katz J Jadad AR Online communities for breast cancer survivors: a review and analysis of their characteristics and levels of use Support Care Cancer 2013 05 21 5 1253 63 10.1007/s00520-012-1655-9 23179491 23179491 · DOI
  52. [63]Ector GI Govers TM Westerweel PE Grutters JP Blijlevens NM The potential health gain and cost savings of improving adherence in chronic myeloid leukemia Leuk Lymphoma 2019 06 60 6 1485 92 10.1080/10428194.2018.1535113 30668187 30668187 · DOI

Cited by

Sorted by citations

  • User-Centered Design for Digital Patient-Navigation Tools in Oncology: Scoping Review

    Kheirinejad, S., White, B. M., Kheirkhah Rahimabad, P., Zink, J. A., Hashtarkhani, S., Kumsa, F. A., Rashid, R., Chinthala, L., Brett, C. L., Davis, R. L., et al. (2026) · JMIR Human Factors · doi:10.2196/87686

    “Studies such as CMyLife [14] and iNNOVBC [20] illustrate how patient-centered platforms were developed and iteratively refined through user feedback, leading to improvements in navigation, personalization, and care coordination features.”
    Influential

Authors
Ector, G. I., Westerweel, P. E., Hermens, R. P., Braspenning, K. A., Heeren, B. C., Vinck, O. M., de Jong, J. J., Janssen, J. J., & Blijlevens, N. M.
Affiliations
  • Radboud University Medical Center (NL)
  • Albert Schweitzer Ziekenhuis (NL)
  • Amsterdam University Medical Centers (NL)
Corresponding author
Ector, Geneviève ICG
ORCID
Venue
Journal of Medical Internet Research
Publisher
JMIR Publications Inc.
Published
2020-05-15
Volume
22
Issue
5
Pages
e15895
ISSN
1438-8871 (ISSN-L)
DOI
10.2196/15895
PMC
PMC7260663
OpenAlex
W3021481856
Cited by
57
References
3
Citations by year
2026: 6 · 2025: 11 · 2024: 7 · 2023: 18 · 2022: 7 · 2021: 4 · 2020: 4
FWCI
8.61
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Medical Internet Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Topics
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Physical Sciences › Computer Science › Human-Computer Interaction › Innovative Human-Technology Interaction
  • Physical Sciences › Computer Science › Human-Computer Interaction › Usability and User Interface Design
Keywords
chronic myeloid leukemia, patient-centered interventions, web platform, design thinking, patient empowerment, medication adherence, guideline adherence, tyrosine kinase inhibitors, patient education, symptom monitoring, home blood sampling, home medication delivery
MeSH terms
Adult, Aged, Female, Humans, Male, Middle Aged, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Treatment Outcome, Telemedicine, Patient-Centered Care, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review